EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naive prostate cancer in the era of new AR pathway inhibitors.

被引：2
|
作者：
Grisay, Guillaume
Turco, Fabio
Patrikidou, Anna
Gallardo Diaz, Enrique
McDermott, Raymond S.
Litiere, Saskia
Fournier, Beatrice
Gillessen, Silke
Tombal, Bertrand F.
机构：
[1] Ctr Hosp Jolimont, La Louviere, Belgium
[2] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[3] Inst Gustave Roussy, Villejuif, France
[4] Corporacio Sanitaria & Univ Parc Tauli, Sabadell, Spain
[5] St Vincents Univ Hosp, Canc Trials Ireland, Dublin, Ireland
[6] European Org Reseach & Treatmentfor Canc EORTC, Brussels, Belgium
[7] Clin Univ St Luc, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-137; 261-492-3532-2370-7650-2700; 261-436-2730; 4; 2; 60; 256; 2946; 1917; 162; 1; 38092-25779; 5;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS232
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS232 / TPS232
页数：1
相关论文
共 13 条
  • [1] EORTC 2238 "De-Escalate": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors
    Grisay, Guillaume
    Turco, Fabio
    Litiere, Saskia
    Fournier, Beatrice
    Patrikidou, Anna
    Gallardo, Enrique
    Mcdermott, Ray
    Alanya, Ahu
    Gillessen, Silke
    Tombal, Bertrand
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [2] Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naive bone-metastatic prostate cancer
    Ebbinge, Maria
    Berglund, Anders
    Section, Eberhard Varenhorst
    Hedlund, Per Olov
    Sandblom, Gabriel
    BJU INTERNATIONAL, 2018, 122 (04) : 583 - 591
  • [3] Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naive metastatic prostate cancer patients - A propensity scoring approach
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    Nozawa, Masahiro
    Hara, Isao
    Nishioka, Tsukasa
    Komura, Takahiro
    Esa, Atsunobu
    Uejima, Shigeya
    Imanishi, Masaaki
    Uekado, Yasunari
    Ogawa, Takatoshi
    Kajikawa, Hiroshi
    Uemura, Hirotsugu
    ASIAN JOURNAL OF UROLOGY, 2016, 3 (01) : 33 - 38
  • [4] A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).
    Tombal, Bertrand F.
    Gomez-Veiga, Francisco
    Gomez-Ferrer, Alvaro
    Lopez-Campos, Fernando
    Ost, Piet
    Roumeguere, Thierry Andre
    Herrera-Imbroda, Bernardo
    D'Hondt, Lionel A.
    Quivrin, Magali
    Gontero, Paolo
    Villa, Salvador
    Khaled, Hussein Mustafa
    Fournier, Beatrice
    Krzystyniak, Joanna
    Pretzenbacher, Yassin
    Erkol, Hazal
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
    Fiorica, Francesco
    Buttigliero, Consuelo
    Grigolato, Daniela
    Muraro, Marco
    Turco, Fabio
    Munoz, Fernando
    Tucci, Marcello
    CURRENT ONCOLOGY, 2022, 29 (12) : 9511 - 9524
  • [6] PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403)
    Gravis, G.
    Fizazi, K.
    Joly, F.
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [7] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
    Fizazi, Karim
    Tran, Namphuong
    Fein, Luis Enrique
    Matsubara, Nobuaki
    Antolin, Alfredo Rodriguez
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary Beth
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
    Fizazi, Karim
    Namphuong Tran
    Enrique Fein, Luis
    Matsubara, Nobuaki
    Rodriguez Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary Beth
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [9] Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.
    Lavaud, Pernelle
    Gravis, Gwenaelle
    Legoupil, Clemente
    Joly, Florence
    Oudard, Stephane
    Priou, Franck
    Mourey, Loic
    Soulie, Michel
    Latorzeff, Igor
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Theodore, Christine
    Ferrero, Jean Marc
    Beuzeboc, Philippe
    Habibian, Muriel
    Foulon, Stephanie
    Boher, Jean Marie
    Tergemina-Clain, Gabrielle
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Metastatic disease detection is an important cause of screen failures in a phase II trial evaluating the optimal sequence of androgen deprivation therapy and sipuleucel-T in hormone-naive patients with biochemically-recurrent prostate cancer (BRPC)
    Kibel, A.
    Drake, C.
    Yu, E.
    Adams, G.
    Karsh, L.
    Elfiky, A.
    Vogelzang, N.
    Shore, N.
    Tyler, R.
    Antonarakis, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S697 - S698
12